More back and forth as Abbvie talks up benefits of Shire acquisiton

LONDON – Is it the tax break or the products? Abbvie Inc. launched its public campaign to acquire Shire plc for $47 billion, promising synergies in the pipelines and the opportunity to use its marketing heft to expand Shire's rare diseases and attention deficit hyperactivity disorder (ADHD) franchises.